ReviewJournal of Alzheimer's disease : JAD2025
Obesity and Alzheimer's disease dementia: Examining inflammatory links to cognitive decline and neuropsychiatric symptoms.
Review in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anti-obesity medications and cognitive disorder risk: a discrepancy between RCTs and real-world evidence.Frontiers in pharmacology · 2026Pooled it
- Association between extreme temperature events and intrinsic capacity trajectories among middle-aged and older adults: the China Health and Retirement Longitudinal Study (CHARLS).BMC public health · 2026Article
- Multi-omics identification of haptoglobin as a novel target for increased Alzheimer's disease risk associated with obesity through inhibiting the phagocytosis of Aβ by disease-associated microglia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Vestibular dysfunction: a hidden risk factor for Alzheimer's disease.Journal of neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is recognized as a risk factor for cardiovascular disease, vascular dementia, and Alzheimer's disease dementia (AD dementia). Emerging evidence indicates that obesity in AD patients is associated with heightened neuropsychiatric symptoms, as reflected by inflammatory biomarkers such as C-reactive protein and complement C3. Neuroinflammation, particularly through certain aspects of microglial activation, plays a significant role in AD development and cognitive decline. While further research is warranted to explore these neuroinflammatory pathways as potential therapeutic targets, proactive weight management starting in middle age may help mitigate both cognitive decline and neuropsychiatric symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.